Title:
COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENTS
Document Type and Number:
WIPO Patent Application WO/2018/070390
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a pharmaceutical composition and the like used for treating or preventing angiogenic diseases. This pharmaceutical composition is a combination of a monoclonal antibody or antigen-binding fragment thereof having features (i) to (v) below, and a VEGF antagonist; or includes said antibody or antigen-binding fragment thereof, and a VEGF antagonist: (i) feature of binding to ROBO4 protein with a Kd value of 1×10-8 M or less; (ii) feature of specifically binding to human ROBO4 protein shown in SEQ ID NO: 2 of the Sequence Listing; (iii) feature of suppressing or inhibiting in vitro migration of vascular endothelial cells in the absence of a crosslink antibody; (iv) feature of suppressing or inhibiting angiogenesis in vivo; and (v) feature of being a chimeric antibody or a humanized antibody.
More Like This:
| WO/2018/088877 | ANTIBODY BINDING SPECIFICALLY TO CD66C AND USE THEREOF |
| WO/2003/029413 | A NOVEL G PROTEIN-COUPLED RECEPTOR, GAVE 10 |
| WO/2017/149306 | COMBINATION THERAPY |
Inventors:
ISUMI YOSHITAKA (JP)
Application Number:
PCT/JP2017/036721
Publication Date:
April 19, 2018
Filing Date:
October 11, 2017
Export Citation:
Assignee:
DAIICHI SANKYO CO LTD (JP)
International Classes:
A61K39/395; A61K31/7088; A61K38/02; A61K45/00; A61P27/02; A61P27/06; A61P37/06; A61P43/00; C07K16/18; C12N15/09
Domestic Patent References:
| WO1998045331A2 | 1998-10-15 | |||
| WO2000075319A1 | 2000-12-14 | |||
| WO2008073441A2 | 2008-06-19 | |||
| WO2013160879A1 | 2013-10-31 | |||
| WO1990007861A1 | 1990-07-26 |
Foreign References:
| JP2015515490A | 2015-05-28 | |||
| US6972323B1 | 2005-12-06 | |||
| US4946778A | 1990-08-07 | |||
| US5260203A | 1993-11-09 | |||
| US5091513A | 1992-02-25 | |||
| US5455030A | 1995-10-03 | |||
| US6214388B1 | 2001-04-10 |
Other References:
KOIZUMI, HIDEKI: "Treatment of Age-relatedMacular Degeneration 2) Anti-VEGF Theraphy", PROGRESS IN MEDICINE, vol. 33, no. 10, 2013, pages 2107 - 2111, XP009514045, ISSN: 0287-3648
WYGLEDOWSKA-PROMIENSKA, DOROTA ET AL.: "Combination o: Aflibercept andBromfenac Therapy in Age-RelatedMacula Degeneration: A Pilot Study Aflibercept and Bromfena in AMD", MEDICAL SCIENCE MONITOR, vol. 21, 2015, pages 3906 - 3912, XP055476603
See also references of EP 3527225A4
CANCER RES, vol. 57, no. 20, 1997, pages 4593 - 4599
GENOMICS, vol. 79, no. 4, 2002, pages 547 - 552
NATURE MEDICINE, vol. 14, 2008, pages 448 - 453
MOLECULAR VISION, vol. 15, 2009, pages 1057 - 1069
CANCER CELL, vol. 19, 2011, pages 101 - 113
NATURE, vol. 8, 2008, pages 34 - 47
CANCER RES, vol. 71, 2011, pages 5670 - 5677
NATURE, vol. 321, 1986, pages 522 - 525
GERGER ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 2, 1987, pages 785 - 794
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134
BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
"Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
WYGLEDOWSKA-PROMIENSKA, DOROTA ET AL.: "Combination o: Aflibercept andBromfenac Therapy in Age-RelatedMacula Degeneration: A Pilot Study Aflibercept and Bromfena in AMD", MEDICAL SCIENCE MONITOR, vol. 21, 2015, pages 3906 - 3912, XP055476603
See also references of EP 3527225A4
CANCER RES, vol. 57, no. 20, 1997, pages 4593 - 4599
GENOMICS, vol. 79, no. 4, 2002, pages 547 - 552
NATURE MEDICINE, vol. 14, 2008, pages 448 - 453
MOLECULAR VISION, vol. 15, 2009, pages 1057 - 1069
CANCER CELL, vol. 19, 2011, pages 101 - 113
NATURE, vol. 8, 2008, pages 34 - 47
CANCER RES, vol. 71, 2011, pages 5670 - 5677
NATURE, vol. 321, 1986, pages 522 - 525
GERGER ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 2, 1987, pages 785 - 794
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134
BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
"Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
Attorney, Agent or Firm:
ISHIBASHI, Koki et al. (JP)
Download PDF: